총 159페이지
145페이지 본문시작
제5장.항생제감수성검사
TableA.2.가축및축산물유래Escherichiacoli /Salmonella spp.의MIC검사에사용한항생제종류및breakpoints
Antimicrobial
AntimicrobialAgents
Rangetested
Breakpoints
Reference
subclass
(Abbreviation)
1)
Gentamicin(GEN)
1∼64
≥16
CLSI
Aminoglycosides
2)
Streptomycin(STR)
16∼128
≥32
NARMS
1)
Aminopenicillin
Ampicillin(AMP)
2∼64
≥32
CLSI
β∼lactam/β∼lactamase
Amoxicillin/
1)
2/1∼32/16
≥32/16
CLSI
inhibitorcombinations
clavulanicacid(AMC)
1)
Cephamycin
Cefoxitin(FOX)
1∼32
≥32
CLSI
2)
Ceftiofur(XNL)
0.5∼8
≥8
NARMS
CephalosporinⅢ
1)
Ceftazidime(CAZ)
1∼16
≥16
CLSI
1)
CephalosporinIV
Cefepime(FEP)
0.25∼16
≥16
CLSI
1)
Carbapenem
Meropenem(MEM)
0.25∼4
≥4
CLSI
1)
Fluoroquinolone
Ciprofloxacin(CIP)
0.12∼16
≥1
CLSI
Trimethoprim/
1)
0.12/2.38∼4/76
≥4/76
CLSI
Sulfamethoxazole(SXT)
Folatepathwayinhibitors
1)
Sulfisoxazole(FIS)
16∼256
≥512
CLSI
1)
Phenicols
Chloramphenicol(CHL)
2∼64
≥32
CLSI
3)
Polymyxins
Colistin(COL)
2∼16
≥4
EUCAST
1)
Quinolone
Nalidixicacid(NAL)
2∼128
≥32
CLSI
1)
Tetracyclines
Tetracycline(TET)
2∼128
≥16
CLSI
1)ClinicalLaboratoryStandardsInstitute,M100,2021
2)NationalAntimicrobialResistanceMonitoringSystem,2021
3)EuropeanCommitteeonAntimicrobialSusceptibilityTesting,2019
TableA.3.가축및축산물유래Enterococcusfaecium/ 의MIC검사에사용한항생제종류및breakpoints
Antimicrobial
AntimicrobialAgents
Rangetested
Breakpoints
Reference
subclass
(Abbreviation)
(㎍/㎖)
(㎍/㎖)
6)
Gentamicin(GEN)
128∼2,048
≥1,024
NARMS
2)
Aminoglycosides
Kanamycin(KAN)
128∼2,048
≥1,024
NARMS
6)
Streptomycin(STR)
128∼2,048
≥1,024
NARMS
1)
Aminopenicillin
Ampicillin(AMP)
1∼16
≥16
CLSI
1)
Fluoroquinolone
Ciprofloxacin(CIP)
0.25∼16
≥4
CLSI
1)
Glycopeptide
Vancomycin(VAN)
2∼32
≥32
CLSI
6)
Glycylcyclines
Tigecycline(TGC)
0.12∼2
≥0.5
DANMAP
1)
Lipopeptides
Daptomycin(DAP)
0.5∼32
≥8
CLSI
1)
Erythromycin(ERY)
1∼64
≥8
CLSI
Macrolides
2)
Tylosin(TYL)
1∼64
≥32
NARMS
1)
Oxazolidinones
Linezolid(LNZ)
0.5∼16
≥8
CLSI
1)
Chloramphenicol(CHL)
2∼32
≥32
CLSI
Phenicols
4)
Florfenicol(FFC)
2∼32
≥16
DANMAP
1)
Streptogramins
Quinupristin/Dalfopristin(SYN)
1∼32
≥4
CLSI
1)
Tetracyclines
Tetracycline(TET)
2∼128
≥16
CLSI
5)
Others
Salinomycin(SAL)
2∼32
≥8
DANMAP
1)ClinicalLaboratoryStandardsInstitute,M100,2021
2)NationalAntimicrobialResistanceMonitoringSystem,2015
3)TheDanishIntegratedAntimicrobialResistanceMonitoringandResearchProgramme,2019
4)TheDanishIntegratedAntimicrobialResistanceMonitoringandResearchProgramme,2007
5)TheDanishIntegratedAntimicrobialResistanceMonitoringandResearchProgramme,2013
6)NationalAntimicrobialResistanceMonitoringSystem,2021
141
TableA.2.가축및축산물유래Escherichiacoli /Salmonella spp.의MIC검사에사용한항생제종류및breakpoints
Antimicrobial
AntimicrobialAgents
Rangetested
Breakpoints
Reference
subclass
(Abbreviation)
1)
Gentamicin(GEN)
1∼64
≥16
CLSI
Aminoglycosides
2)
Streptomycin(STR)
16∼128
≥32
NARMS
1)
Aminopenicillin
Ampicillin(AMP)
2∼64
≥32
CLSI
β∼lactam/β∼lactamase
Amoxicillin/
1)
2/1∼32/16
≥32/16
CLSI
inhibitorcombinations
clavulanicacid(AMC)
1)
Cephamycin
Cefoxitin(FOX)
1∼32
≥32
CLSI
2)
Ceftiofur(XNL)
0.5∼8
≥8
NARMS
CephalosporinⅢ
1)
Ceftazidime(CAZ)
1∼16
≥16
CLSI
1)
CephalosporinIV
Cefepime(FEP)
0.25∼16
≥16
CLSI
1)
Carbapenem
Meropenem(MEM)
0.25∼4
≥4
CLSI
1)
Fluoroquinolone
Ciprofloxacin(CIP)
0.12∼16
≥1
CLSI
Trimethoprim/
1)
0.12/2.38∼4/76
≥4/76
CLSI
Sulfamethoxazole(SXT)
Folatepathwayinhibitors
1)
Sulfisoxazole(FIS)
16∼256
≥512
CLSI
1)
Phenicols
Chloramphenicol(CHL)
2∼64
≥32
CLSI
3)
Polymyxins
Colistin(COL)
2∼16
≥4
EUCAST
1)
Quinolone
Nalidixicacid(NAL)
2∼128
≥32
CLSI
1)
Tetracyclines
Tetracycline(TET)
2∼128
≥16
CLSI
1)ClinicalLaboratoryStandardsInstitute,M100,2021
2)NationalAntimicrobialResistanceMonitoringSystem,2021
3)EuropeanCommitteeonAntimicrobialSusceptibilityTesting,2019
TableA.3.가축및축산물유래Enterococcusfaecium/ 의MIC검사에사용한항생제종류및breakpoints
Antimicrobial
AntimicrobialAgents
Rangetested
Breakpoints
Reference
subclass
(Abbreviation)
(㎍/㎖)
(㎍/㎖)
6)
Gentamicin(GEN)
128∼2,048
≥1,024
NARMS
2)
Aminoglycosides
Kanamycin(KAN)
128∼2,048
≥1,024
NARMS
6)
Streptomycin(STR)
128∼2,048
≥1,024
NARMS
1)
Aminopenicillin
Ampicillin(AMP)
1∼16
≥16
CLSI
1)
Fluoroquinolone
Ciprofloxacin(CIP)
0.25∼16
≥4
CLSI
1)
Glycopeptide
Vancomycin(VAN)
2∼32
≥32
CLSI
6)
Glycylcyclines
Tigecycline(TGC)
0.12∼2
≥0.5
DANMAP
1)
Lipopeptides
Daptomycin(DAP)
0.5∼32
≥8
CLSI
1)
Erythromycin(ERY)
1∼64
≥8
CLSI
Macrolides
2)
Tylosin(TYL)
1∼64
≥32
NARMS
1)
Oxazolidinones
Linezolid(LNZ)
0.5∼16
≥8
CLSI
1)
Chloramphenicol(CHL)
2∼32
≥32
CLSI
Phenicols
4)
Florfenicol(FFC)
2∼32
≥16
DANMAP
1)
Streptogramins
Quinupristin/Dalfopristin(SYN)
1∼32
≥4
CLSI
1)
Tetracyclines
Tetracycline(TET)
2∼128
≥16
CLSI
5)
Others
Salinomycin(SAL)
2∼32
≥8
DANMAP
1)ClinicalLaboratoryStandardsInstitute,M100,2021
2)NationalAntimicrobialResistanceMonitoringSystem,2015
3)TheDanishIntegratedAntimicrobialResistanceMonitoringandResearchProgramme,2019
4)TheDanishIntegratedAntimicrobialResistanceMonitoringandResearchProgramme,2007
5)TheDanishIntegratedAntimicrobialResistanceMonitoringandResearchProgramme,2013
6)NationalAntimicrobialResistanceMonitoringSystem,2021
141
145페이지 본문끝
메뉴
현재 포커스의 아래내용들은 동일한 컨텐츠를 가지고 페이지넘김 효과및 시각적 효과를 제공하는 페이지이므로 스크린리더 사용자는 여기까지만 낭독하시고 위의 페이지이동 링크를 사용하여 다음페이지로 이동하시기 바랍니다.